Galderma Readies Its First Therapeutic Biologic For Two US Launches In 2024

Phase III Data Also Show New Toxin Works Up To Six Months

 
• By Mandy Jackson

Galderma said its IL-31 receptor alpha inhibitor nemolizumab succeeded in two Phase III atopic dermatitis trials, advancing the firm’s long-term goal of moving past topical dermatology drugs.

Wooden blocks with launching rocket graphic arranged in pyramid shape
Galderma is building up to its nemolizumab launch in the US next year • Source: Shutterstock

More from Dermatological

More from Therapy Areas